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Intra-osseous schwannoma is a rare mesenchymal tumor. Although, the head and neck region is one of the most
common sites for schwannomas, its location at the skull bone is uncommon and accounted for less than 0.2% in
the largest series of bone tumors ever reported. Furthermore, it is most often a benign tumor, malignant
transformation is exceedingly rare.
Clinical presentation is non-specific, most often symptoms are associated with compression and invasion of adjacent
organs. Neuro-imaging features are non-specific and the diagnosis is based on histological examination with
immunohistochemical study.
Surgery remains the aim of treatment. However, radiation therapy could be an interesting therapeutic option in
unresectable tumors.
This systemic review offers new clinicopathological data useful for better defining the diagnosis and clinicopathological
behavior of schwannoma. The purpose of this work is to raise awareness among clinicians adding this clinical entity as
a differential diagnosis when a mass of skull bone is identified.
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Schwannoma also referred to as neurilmoma, neurinoma,
and perineural fibroblastoma is a solitary soft tissue or
intra-bone lesion, most often developped from a Peripheral
nerve [1].
Schwannoma arising from Schwann cells, first described
by Verocay in 1910, is most often a benign tumor, ma-
lignant transformation is exceptional [1]. Intraosseous
schwannoma is a rare mesenchymal tumor, its location at
the skull bone is extremely rare [1-3]. There are few re-
ports of individual cases [1,2,4-6], but no large series from
a single institution has been published yet.Review
Intraosseous schwannomas are known to account for
less than 0.2% of primary bone tumors [1,3]. To the best* Correspondence: fadouarais@gmail.com
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tosis disease have been described to date.
Clinical presentation is non-specific, most often symp-
toms are associated with compression and invasion of
adjacent organs. The diagnosis is based on histological
examination with immunohistochemical study [1,7]. Sur-
gery is the mainstay of treatment, however, radiotherapy
remains the salvage treatment for unresectable tumors [8].
Through this review of the literature, we try to illuminate
this extremely rare pathology. It is necessary to distinguish
malignant tumors usually occuring in the context of Von
Reclinghausen disease, from benign schwannomas [9]. In
fact, these entities are different by their clinical and patho-
logical behaviors. In order to avoid confusion between
them, we try to treat separately the two entities.Classification
The new World Health Organization (WHO) classifica-
tion [10] of soft tissue tumours, published in 2013, incor-
porates for the first time peripheral nerve sheath tumours.is is an Open Access article distributed under the terms of the Creative
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tion of the central nervous system. Overall, the WHO felt
that these groups of lesions fitted better under the heading
of ‘Soft tissue tumours’, and this allows a more compre-
hensive classification [11].
According to this classification, schwannoma (including
variants) is a begnin entity, whereas malignant schwanoma
is included under the name of malignant peripheral nerve
sheath tumour (MPNST). This WHO classification of
sheath nerve tumours is resumed in Table 1 [12].
1. Benign Schwannoma.
Patient demographics
Intraosseous schwannomas affect males and females
equally, with patient age ranging from 2 to 65 years. The
mandible is the most common location, followed by
sacrum. Other sites such as vertebra, ulna, humerus,
femur, tibia, patella, scapula, rib, and small bones of the
hands have been reported [13].
Approximately 25% of the reported cases originate
from the head and neck region [1]. However, intra-
osseous schwannoma of the skull bone are very rare,
accounted for less than 0.2% of primary bone tumors
[1-3]. Data are available from published isolated case re-
ports and small case series. The first documented case
in the literature was published by Solodnik and al in
1986 [5,14].
In one of the most important reviews of intraosseous
schwannoma, Gordon and al presumed that the diagnosis
of this entity might be missed because of its rarity and
atypical roentgenologic appearance [15].Table 1 WHO classification of soft tissue tumours (2013)
including for the first time nerve sheath tumours [12]
Nerve sheath tumours
Benign Malignant
Schwannoma (including variants) Malignant peripheral nerve
sheath tumour
Melanotic schwannoma Epithelioid malignant nerve
sheath tumour
Neurofibroma (including variants) Malignant Triton tumour










Hybrid nerve sheath tumoursHistogenesis
Schwannoma is associated with sensory nerves. There-
fore, the exceedingly rare occurrence of intraosseous
schwannoma is due to the low density of sensory nerve
fibers within bone [2,13,16]. Schwannomas can involve
bone by 3 mechanisms [1,2,16].
a) Tumor may arise centrally within the bone,
b) Tumor can arise within the nutrient canal and
produce canal expansion: tumors grow in a
dumbbell-shaped configuration, enlarging the canal
c) Extraosseous tumors can cause secondary erosion of
bone: a soft tissue or periosteal tumor may cause
secondary erosion of the bone and penetration into.
However, the histological origin of such intra-osseous
schwannoma remains controversial. In fact, hyperplastic
schwann cells of the perivascular nerve plexus, especially
of autonomic nerves could explain the development of
meningeal schwannoma [17], and even intraosseous
schwannoma [18]. Also, schwannosis which is an hamar-
tomatous lesion consisting of Schwann cells and related
reticulin fibers could not be excluded in histogenesis of
such lesion [5,19].
Histopathology
Histologic features of intraosseous schwannomas are usu-
ally similar to that observed for soft-tissue schwannomas
including Antoni A type (characterized by Schwann cells
closely packed and arranged in bundles or rows with palis-
ading nuclei) and Antoni B type (with less number of cells
and disorganization of fusiform cells dispersed in a loose
and random fashion) tissue arrangements [1,13].
Schwannoma is an encapsulated neoplasm, character-
ized by slow growing and low invasive potential, it rarely
undergoes malignant transformation [20,21].
Important features to suggest a benign diagnosis in-
clude absence of infiltrative margins (sharp circumscrip-
tion), perivascular hyalinization, disproportionally high
cellularity when compared to the degree of nuclear aty-
pia or mitotic activity, and strong and uniform immuno-
staining for S-100 protein [20,22].
A diagnosis of schwannoma with uncertain malignant
potential could be evoked in front of a locally aggres-
sive growth pattern in a histologically benign-appearing
tumor [20].
Immunohistochemistry
The histological diagnosis of schwannoma is difficult be-
cause of the similarity with other sarcomas, so pathologists
use S100 protein which is specific for nervous cells [7,23].
In fact, Immunohistochemically, schwannoma is nearly
uniformly positive for the S-100 protein and for
vimentine [1].
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Clinical symptoms of schwannoma are not specific and
depend on the location. They are most often related to
compression of adjacent organs or of their invasion [7].
The skull bone is an exceedingly rare site for intraoss-
eous schwannoma. Only 10 cases of this location have
been reported previously (Table 2).
The first documented case in the literature was pub-
lished by Solodnik and al in 1986, they described an
intraosseous neurinoma of petrous apex of a 59 year-old
man with headache, tinnitus in the right ear, and un-
steadiness [14].
Ersahin and al reported a case of intraoessous schwan-
noma of parietal bone of a 4-year-old boy presented with
a lump on the right side of his head with a mass witch
enlarged in size progressively [13].
The patient reported by Schiffer and al in 1991 was a
3-year-old boy with a non tender mass in the left fronto-
orbital region [6].
Sphenoidal schwannoma resembles other primary tu-
mors of the sphenoid in symptomatology and physical
signs [5,6]. In fact, El bahy and al reported a case of
spheno-orbital bone of a 40-year-old man with proptosis
and impairment of lateral gaze movement of his left eye
and a palpable soft non tender swelling at the left fron-
tozygomatic junction [5].
Two others cases was reported by Celli.P and al, the first
of occipital bone and the second of frontal bone, both of
them presented with a hard non tender mass [24].
Another case of frontal bone reported by Goyal R and al
of an 11-year-old boy presented with forehead swelling
that increased progressively during a period of 2 years [2].Table 2 Solitary intraosseous schwannoma of the vault and t
Authors Age Sex Site Pr
Solodnik et al.
(1986) [14]









Report of two cases ? Skull bone ?
Celli et al.
(1998) [24]
14-year Male Frontal bone Ha
3-year Male Occipital bone Ha
Ersahin et al.
(2000) [13]
4-year Male Parietal bone A






Goyal R et al.
(2008) [2]
11-year Male Frontal bone Fo
Amita et al.
(2014) [25]
41-year Female Frontal bone Pa
he
ge
seRecently R.Amita published another case of frontal
bone in a 41-year-old female presented with insidious
onset intermittent paresthesia in right upper and lower
limbs and left hemicranial headache with two episodes
of generalized tonic-clonic seizures [25]. Unni and al re-
ported 2 cases of intraosseous schwannoma of the skull
but without more detailed information [26].
Physical examination, in all reported cases was normal,
especially without neurological deficits.
Approximately 10% of schwannomas are associated with
multisystem disorders such as neurofibromatosis, schwan-
nomatosis, multiple meningiomas, and Carney complex
[20]. However, these disorders have not been present in
anyone of previously cited cases.
Neuro-imaging features
The preoperative diagnosis is often difficult, as the neuro-
imaging features are non-specific, but it contributes to
evaluate the extent and determine infiltration of the adja-
cent structures [1].
At CT scan, intraosseous schwannomas are most often
present as a lytic lesion, with sclerotic borders, or as a
sharply demarcated defect that often expand the involved
bone. Perilesional sclerosis may surround the area of cen-
tral lucency [2], and sometimes spotted calcifications may
be seen [13]. Furthermore, it may be presented as a soft-
tissue mass with bone erosion [13].
MRI showed an inhomogeneous lesion on T1-weighted
spin-echo images, hyperintense signal on T2-weighted
spin-echo images, and isointense on T2-fast images. The
lesion showed peripheral intense enhancement with gado-
linium [13,24].he base of the skull patient characteristics
incipals symptoms Treatment Follow up Outcome
adache, tinnitus, and
steadiness.
Sub-total excision ? Good
non tender mass Total good excision 1 year Good
? ? ?
rd non tender mass Complete excision 2 year Good
rd non tender mass Complete excision 14 year Good
non tender solid mass Totalexcision 2 year Good
ptosis, swelling of the
ntozygomatic junction
Complete excision ? Good





Complete excision 3 months Good
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nerve sheath tumour (MPNST).
Malignant peripheral nerve sheath tumour (MPNST)
is a rare aggressive tumor, which represents 5% of soft
tissue sarcomas. Nevertheless, there was a resurgence of
this condition in patients with Von Recklinghausen dis-
ease [7].
MPNST of the head and neck is extremely rare [27]
and has not been reported in an intraosseous skull bone
location. Although occasional neoplasms have been re-
ported in the maxilla, mandible, palate and other sites.
The mandible is the most commonly invaded structure
in the oral area [27-30].
Otherwise, solitary malignant schwannoma is very
uncommon. In a large series of 232 patients with soli-
tary malignant schwannomas, not associated with Von
Recklinghausen’s disease, reported by Tapas and all
[31], eighteen (7%) tumors were in the head and neck
but none of them was intraosseous.
The microscopic diagnosis of MPNST is difficult because
the tumors often consist of fusiform elements packed in
interlacing bundles and resemble fibrosarcoma [31].
Malignancy is retained on cell pleomorphism, high
number of mitosis and capsular infiltration [7,23]. Also,
the lack of well-delimited borders and encapsulation, in-
vasion signs, significant atypia and necrosis suggest ma-
lignancy [32]. Large areas of necrosis and high mitotic
activity are typical [21].
In contrast to benign and locally aggressive schwanno-
mas, which demonstrate uniform immunoreactivity for
S-100 protein, malignant entity may show patchy or ab-
sent immunoreactivity for this antigen [10].
There is no clinical findings characteristic of MPNST.
In head and neck reported cases, the chief reason the
patient seeks advice is a soft tissue mass which is grad-
ually enlarging [31].
Prognostic factors are tumor size, grade of malignancy,
speed of clinical evolution, degree of cellular pleomorph-
ism and mitotic activity [7].
For malignant peripheral nerve sheath tumor (MPNST),
the 5-year survival is ranged from 50 to 55% in patients
without neurofibromatosis but it is reduced to less than
20% in patients with this disease [7,33]. They tend to recur
(40%–65%) and metastasize (40%–80%) [34].
Treatment
All reported cases in the literature were benign, there-
fore intraosseous schwannoma was treated by complete
excision in most cases. They registered a good outcome
with no local recurrence within a follow-up that ranged
from 3 months to 14 years.
The optimal treatment for intraosseous schwannoma
has not been well established given the rarity of this entity.Total resection of intraosseous schwannomawas described
as a sufficient treatment, in particular for limited tumors
without invasion of adjacent structures. However, only vol-
ume reduction, without total removal or tumor control can
be achieved with a surgical approach in others cases [35].
Radical excision is based on location, shape, size and
local spread. The tumor plus its bed and any attached
structures should be resected en bloc [31].
As alternative treatment, stereotactic radiosurgery and
radiotherapy may be performed, when the tumor is
unresectable. In fact, the extent of the resection and po-
tential morbidity must be considered in addition to
accessing the region of interest [35].
Therefore, radio surgery may be suggested when micro-
surgical resection is contraindicated, as well as for patients
with serious comorbidities or underlying neurofibroma-
tosis, which often involves multiple lesions [4].
The effect of radiotherapy has been studied in various
schwannomas and has been shown to be effective in pre-
venting tumor growth, although long-term assessments
of the benefits in patient quality of life remain uncertain.
Little is known about the comparative efficacy of stereo-
tactic radiotherapy to surgery [8].
The use of pre or post-operative adjuvant therapy is
not yet well codified, but in case of incomplete resection,
radiotherapy can be envisaged [1,7].
The role of chemotherapy in advanced malignant per-
ipheral nerve sheath tumor (MPNST) is unclear. Most
MPNSTs are biologically high-grade sarcomas that tend to
recur (40%–65%) and metastasize (40%–80%). MPNST
usually metastasize most commonly to the lungs [34].
Because of the rarity of MPNST, consistent data re-
garding chemotherapy sensitivity are lacking. As for
other unresectable and metastatic soft tissue sarcoma,
doxorubicin and ifosfamide are generally considered to
be the most active chemotherapeutic agents.
In a recent study of EORTC soft tissue and bone sar-
coma group study, that compares the outcome of patients
with advanced MPNST, with those with other soft tissue
sarcoma histological subtypes, the findings showed that,
compared with standard first-line doxorubicin, the doxo-
rubicin–ifosfamide regimen had the best response, whereas
ifosfamide had the worst prognosis. Results of an ongoing
NCI multicenter phase II trial (NCT00304083) that studies
combination chemotherapy with doxorubicin, etoposide
and ifosfamide in unresectable (stages III–IV) adult
MPNST are awaited [34].
Conclusion
The purpose of this review is to offer new clinicopatho-
logical data of intraosseous schwannomas of skull bone,
useful for better defining the diagnosis and biological
behavior of schwannoma specially in such unusual
location.
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radiation could be an interesting therapeutic option for
unresectable tumors. This paper aims to raise aware-
ness among clinicians adding this clinical entity as a
differential diagnosis when a mass of skull bone is
identified.
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